Pharmacyte Biotech Inc (PMCB) 0.0308 $PMCB PharmaCyte's

New Post Public Reply Private Reply Replies (0) Message Board

Sep 17, 2016 at 9:14 AM

Pharmacyte Biotech Inc (PMCB) 0.0308 $PMCB

PharmaCyte's CEO Discusses Development of its Pancreatic Cancer Therapy
GlobeNewswire - Thu Sep 15, 8:15AM CDT
PharmaCyte Biotech, Inc. (OTCQB

MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today addressed shareholders on the development of PharmaCyte's therapy for advanced pancreatic cancer.

PharmaCyte Biotech Reports on Progress in Its Medical Cannabis Program
GlobeNewswire - Thu Sep 01, 8:35AM CDT
PharmaCyte Biotech, Inc. (OTCQB

MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today provided an update on its program for developing treatments for serious brain cancers that involve constituents of the Cannabis plant. These Cannabis-based cancer therapies, like PharmaCyte's pancreatic cancer therapy, will involve the use of its Cell-in-a-Box technology. The cancer "prodrug" that will be activated (converted to their cancer-killing forms) by the cells inside the Cell-in-a-Box capsules are constituents of the Cannabis plant known as cannabinoids. PharmaCyte has contracted with the University of Northern Colorado (UNCO), led by Dr. Richard M. Hyslop, to conduct the research related to PharmaCyte's medical Cannabis program. UNCO has obtained all of the necessary approvals and has now received research Cannabis to enable it to advance PharmaCyte's program.

Industrial Hemp Operations Expansion Continues To Solidify Itself As An Agricultural Commodity As Reports Show Sales North Of $500Mil Annually
PR Newswire Europe - Tue Aug 23, 7:31AM CDT
CORAL SPRINGS, Florida, August 23, 2016 /PRNewswire/ --

Dr. Mark L. Rabe Presents PharmaCyte Biotech's Ongoing Research at Cannabis Cancer Forum
GlobeNewswire - Tue Aug 02, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB

MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that on Saturday, July 30, 2016, PharmaCyte's Medical and Scientific Advisory Board member Mark L. Rabe, MD, delivered a presentation entitled "Medical Cannabis for Cancer" as part of a "Cannabis for Cancer Forum" in San Diego.

PharmaCyte Biotech Releases Shareholder Call Playback Information
GlobeNewswire - Fri Jul 29, 8:01AM CDT
PharmaCyte Biotech, Inc. (OTCQB

MCB), a clinical stage biotechnology company focused on developing therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that an audio recording of the company's shareholder call, which was held on July 28, 2016, by Chief Executive Officer Kenneth L. Waggoner is now available for playback.

PharmaCyte Biotech Releases Medical and Scientific Discussion from 2016 ASCO Annual Meeting
GlobeNewswire - Thu Jun 23, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB

MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced the release of 5 video presentations that captured PharmaCyte's medical and scientific discussion with oncologists interested in participating in PharmaCyte's Phase 2b clinical trial in advanced, inoperable pancreatic cancer. The discussion session was by invitation only during the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

PharmaCyte Biotech CEO Interviewed Live During Marcum MicroCap Conference
GlobeNewswire - Mon Jun 20, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB

MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte, was interviewed by Stock News Now (SNN) at the 5th Annual Marcum MicroCap Conference in New York City. The SNNLive video interview can be viewed by clicking on the following link: www.PharmaCyte.com/Media.

PharmaCyte Biotech to Present Cancer and Diabetes Therapies at 2016 BIO International Convention
GlobeNewswire - Tue Jun 07, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB

MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that its Chief Executive Officer, Kenneth L. Waggoner, will present PharmaCyte's therapies for cancer and diabetes at this year's BIO International Convention (BIO). Meetings have been scheduled with big pharma potential investors, strategic partners and the media. The 2016 BIO International Convention is being held at the Moscone Center in San Francisco June 6-9, 2016.

PharmaCyte Biotech Officers to Attend Annual Meeting of the American Society of Clinical Oncology
GlobeNewswire - Fri Jun 03, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB

MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that its entire senior management team will attend the American Society of Clinical Oncology's (ASCO) 52nd annual meeting to be held June 3-7, 2016, at McCormick Place in Chicago. The theme of this year's meeting is "Collective Wisdom - The Future of Patient Centered Care and Research."

OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.
LTEA: 4.77 (-0.26)

PharmaCyte Biotech's CEO Featured Speaker at Marcum MicroCap Conference
GlobeNewswire - Tue May 31, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB

MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that the Chief Executive Officer of PharmaCyte will be a featured presenter at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016, in New York City at the Grand Hyatt Hotel. The presentation is scheduled to begin at 9:30 a.m. EDT and will be available via a live webcast. To access the webcast go to http://wsw.com/webcast/marcum4/pmcb.

PharmaCyte Biotech to Present Clinical Trial at Marcum MicroCap, ASCO and BIO International Conferences
GlobeNewswire - Thu May 26, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB

MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte, will be a featured presenter at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016, in New York City at the Grand Hyatt Hotel.

PharmaCyte Biotech to Engage Principal Investigator for Clinical Trial in Pancreatic Cancer
GlobeNewswire - Tue May 24, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB

MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that PharmaCyte has commenced its search for a Principal Investigator for its Phase 2b clinical trial in advanced pancreatic cancer. PharmaCyte will be meeting with potential candidates at this year's annual meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago, Illinois, June 3-7, 2016.

PharmaCyte Biotech Receives 'Notice of Allowance' for Patent Protection of the Melligen Cells to Treat Diabetes
GlobeNewswire - Thu May 12, 8:34AM CDT
PharmaCyte Biotech, Inc. (OTCQB

MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that a Notice of Allowance was received from the U.S. Patent and Trademark Office (USPTO) for patent protection of the human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body (Melligen cells). PharmaCyte plans to encapsulate Melligen cells using the Cell-in-a-Boxtechnology.

PharmaCyte Biotech Clears Major Milestone on Path to FDA Clinical Trial
Marketwire Canada - Thu May 05, 8:15AM CDT
NEW YORK, NY--(Marketwired - May 05, 2016) - PharmaCyte Biotech (OTCQB: PMCB) has now reached a point in its life cycle where it is ready to start working with the U.S. FDA to get the company's Phase 2b clinical trial in advanced pancreatic cancer underway. Let that sink in for a moment. PharmaCyte's Chief Executive Officer, Kenneth L. Waggoner, has taken up the mantle to move the company's signature technology, Cell-in-a-Box®, to the clinic. And now, three short years later, he has the small biotech on the doorstep of what could be an eye-opening clinical trial to treat pancreatic cancer patients.

PharmaCyte Biotech Appoints Former Johnson & Johnson Executive as Senior Business Development Advisor
GlobeNewswire - Tue May 03, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQB

MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that it has appointed Dr. Sanjay Batra as its Senior Business Development Advisor.
JNJ: 118.25 (-0.38)

PharmaCyte Biotech's Live-Cell Encapsulation Facility is Commissioned for GMP Manufacture
GlobeNewswire - Mon Apr 25, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB

MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today reported that the encapsulation facility for its pancreatic cancer therapy is ready to manufacture PharmaCyte's biologic product under current Good Manufacturing Practices (GMP) standards. The facility will be used to encapsulate the live cells used for PharmaCyte's pancreatic cancer therapy. The assessment was issued by Chamow & Associates, the biopharmaceutical consulting firm that specializes in the inspection of facilities for GMP compliance.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lititz Mutual Embraces AI with Guidewire ProNavigator

It's not every day you see a company like Lititz Mutual making moves in the artificial intelligence (AI) arena. Based out of Lititz, Pennsylvania, this insurance firm has decided to shake things up with Guidewire's ProNavigator AI assistant. Forging New Paths in Insurance Lititz Mutual is set to inject some serious tech into their operations. The goal? Make life easier...

Anixa Expands Global Footprint with Aussie Patent

Breaking New Ground in Cancer Immunotherapy Today feels like a pivotal day for Anixa Biosciences. Their announcement about securing a patent in Australia for their trailblazing breast cancer vaccine is like planting a flag on new, promising territory. This is no minor step; it's a strategic leap for the company as it strengthens its intellectual grip on the global...

Annex Brands Grows with Bastrop's PostalAnnex Opening

New PostalAnnex Location Opens in Bastrop, TX Here's a fresh chapter in the books for Annex Brands, Inc. They've just cut the ribbon on a brand spanking new PostalAnnex in Bastrop, Texas, handing the reins over to eager fresh faces, Chetan Modi and Karan Desai. And you know what? This ain't just any regular location. It's a one-stop-shop for anything you could need, from...

U.N. Leaders Converge at NYSE, Forus Soars to $3B Valuation

A Busy Morning at the NYSE with Key Guests and Global Events In a world where high-stakes diplomacy and roaring market bells go hand in hand, today brings the U.S. Secretary of State, Marco Rubio, to the New York Stock Exchange. With the 81st Session of the United Nations General Assembly shaking up the Big Apple, the city finds itself at the intersection of politics and...

Nature-Based Solutions: The Economic And Community Impact

Harnessing Nature to Boost Economies You ever stop to think about how nature itself might just be the best investment? Well, the Walton Family Foundation surely does, betting big on nature-based solutions. Their latest initiative, 'Human Nature,' is shedding light on how these solutions aren't just saving ecosystems — they're fortifying economies and enriching...

HNTB Expands in Capital Region: A Strategic Move

Breaking New Ground in Arlington and Baltimore Deepening their stake in the Capital Region's future, HNTB has thrown open new office doors in Arlington, Virginia, and Baltimore, Maryland. We're not just talking fancy buildings, folks—this is about securing a piece of the infrastructure pie that's only going to get bigger and tastier. Infrastructure's the backbone of...

Navigating AI's New Era: Dresner's 2026 Findings

Big Insights in the AI World of 2026 Well folks, if there's one thing making waves in the boardrooms this year, it's AI. Dresner Advisory Services just threw down a gauntlet for companies with their fresh batch of reports focused on the dizzying world of AI. They ripped right into it, exploring how firms can bag a heap of benefits and deal with the hurdles that come with...

Lawsuit Targets Electrical Consultants' Labor Practices

Trouble Brews at Electrical Consultants, Inc. Right on the heels of a long workday, some employees of Electrical Consultants, Inc. seem to be getting a double whammy. The company is tangled up in a class action lawsuit lodged by the well-known Blumenthal Nordrehaug Bhowmik De Blouw LLP. This ain't your everyday grievance, folks; we're talking meal and rest period...

Tenera Care's Tech Triumph: Halving Falls with Simplicity

Every once in a while, a piece of tech comes along that makes you sit up and say, ‘Now that’s a game-changer!’ And with the recent rave reviews, Tenera Care seems to hit just that sweet spot for folks in the senior living game. By handing Dublin Glenn Memory Care the gold in the KISS category at the 2026 McKnight's Technology Awards, it’s clear the industry is...

Lavior and CR Fitness Team for Wellness Reach

Botanical Care Meets Gym Life in the Southeast Lavior, the botanical whiz kids of wound and skin care out of Miami, are shaking hands with CR Fitness, Crunch's big-time franchise operator carrying the flag across the Southeast. They’ve ironed out a deal that’ll park Lavior’s products in more than 60 gyms covering Florida, Georgia, North Carolina, and Texas. It’s a...